U.S. License Holder:
Astellas
Date of License:
December-18-2019
Last Update:
Dec-15-2024
FDA-Approved Indications
PADCEV (enfortumab vedotin-ejfv) is a Nectin-4-directed antibody and microtubule inhibitor conjugate indicated:
In combination with pembrolizumab for the treatment of adult patients with locally advanced or metastatic urothelial cancer;
As a single agent for the treatment of adult patients with locally advanced or metastatic urothelial cancer who: Have previously received a programmed death receptor-1 (PD-1) or programmed death-ligand 1 (PD-L1) inhibitor and platinum-containing chemotherapy, or are ineligible for cisplatin-containing chemotherapy and have previously received one or more prior lines of therapy;